BPC-157 leaves the bloodstream in under half an hour. Nothing you feel at week six is the peptide still circulating — it is tissue that has had six weeks to rebuild. That single fact explains almost every argument about timing. Connective tissue runs on a fixed biological schedule: inflammation settles in about a day, new collagen goes down over the following weeks, and remodelling does not even begin until roughly week six. No compound compresses that calendar into a weekend.
It also means the honest answer to “how long does BPC-157 take to work” is not a number. It is a different question: what tissue, how badly damaged, and compared to what? Below is the full timeline, what the published research actually measured, and the four reasons people conclude it did nothing.
Type “bpc 157” into Google and watch the suggestions. After the name itself, two phrases dominate: side effects, and how long does it take to work. We covered the first in BPC-157 side effects. This is the second, and it is the harder of the two, because the honest answer disappoints people who want a number.
The question behind the question
When someone asks how long BPC-157 takes to work, they are almost never asking about pharmacology. They are asking one of these:
- “I have been at this three weeks and nothing has changed. Did I waste my money?”
- “How long before I know whether this vial is real?”
- “My shoulder feels better. Was that the peptide, or would it have happened anyway?”
Those are three genuinely different questions, and they have three different answers. The third one is the hardest, and the one almost no online guide will touch, because the honest answer is that in most individual cases you cannot know. We will come back to that in the confounder section, which is the most important part of this article.
BPC-157 is gone in under an hour
Start with the measured pharmacology, because it rules out a whole category of expectation.
A 2022 pharmacokinetics study in Frontiers in Pharmacology followed BPC-157 in rats and dogs. The finding that matters here: the half-life was under 30 minutes. The peptide is broken down into smaller fragments and amino acids and cleared quickly. It does not accumulate. It does not build to a steady state over weeks the way a long-acting compound does.
This is the opposite of how most peptides people discuss actually behave. CJC-1295 with DAC has a measured half-life of roughly 6 to 8 days in humans, which is why it keeps IGF-1 elevated for over a week from one injection. BPC-157 is on the far other end of the scale: by the time you have finished breakfast, the dose is essentially gone.
So if someone tells you the peptide “builds up in your system over a month,” they are describing a different molecule. Whatever BPC-157 does, it does in a short window, repeatedly — and whatever lasts after that is a change in tissue, not a reservoir of drug.
So why would anything take weeks?
Here is the resolution, and it is the central idea of this article.
A compound that clears in 30 minutes can still have effects measured in months, because the thing it acts on is slow. A single signal to a fibroblast — the cell that lays down collagen — does not produce collagen instantly. The cell migrates, multiplies, secretes matrix, and that matrix then has to be cross-linked and reorganised under load. That process has a fixed minimum duration, and it is measured in weeks to months regardless of what you add to it.
Think of it as the difference between sending a work order and the building being finished. The order takes a minute. The build takes a season.
The ceiling on how fast connective tissue can repair is set by biology, not by what you add to it. Any compound is competing to move a tissue timeline slightly, not to replace it. Expectations built on “a few days” were never realistic for tendon or ligament, with or without a peptide.
The three phases of tissue repair
Soft-tissue healing is conventionally divided into three overlapping phases. These are standard sports-medicine and orthopaedic descriptions, not peptide marketing, and they are the backbone of any honest timeline.
| Phase | Window | What is happening | What you would notice |
|---|---|---|---|
| 1. Inflammatory | First ~24 hours, settling over a few days | Platelets and immune cells clear damaged tissue and release signals that recruit fibroblasts | Swelling, heat, pain. This phase is necessary, not a malfunction. |
| 2. Proliferative / repair | Begins within days, runs several weeks | Fibroblasts lay down large amounts of new collagen and matrix. The new tissue is disorganised and weak. | Pain usually eases. Function is still limited. The tissue is not yet strong. |
| 3. Remodelling / maturation | Starts around week 6; fibrous and scar-like by about week 10; continues for months | Collagen cross-links increase, fibres reorganise along lines of load, stiffness and strength peak | Real return of strength and load tolerance. This is the phase people skip in their expectations. |
Two details from this literature deserve emphasis, because they reframe the whole conversation:
- Remodelling does not start until roughly week six. Anyone evaluating a tendon at week three is reading the chapter before the one that matters.
- Healed tendon usually does not regain its pre-injury mechanical properties. That is the baseline reality of tendon repair in general. It is a sobering frame for any claim that a compound restores tissue to new.
Timeline by tissue type
“How long does it take” has no single answer because tissues differ enormously in blood supply and turnover rate. Blood supply is the single best predictor: well-perfused tissue repairs fast, poorly perfused tissue is slow.
| Tissue | Blood supply | Typical repair horizon | Why |
|---|---|---|---|
| Gut lining (mucosa) | Very rich | Days | The epithelium turns over every few days as a matter of routine. The fastest-responding tissue in this list, and the one most of the original BPC-157 research targeted. |
| Skin | Rich | 1–3 weeks for closure, months for scar maturation | High cell turnover, direct access to circulation. |
| Muscle | Rich | Weeks. Average return to play after hamstring strain is around 3 weeks | Good perfusion plus resident satellite cells. |
| Ligament | Moderate to poor | Weeks to many months. Average return after lateral ankle sprain is around 2.5 weeks, but some cases exceed 100 days | Less vascular than muscle, so slower matrix turnover. |
| Tendon | Poor | Months. Remodelling alone starts at week 6 | Low cell density, low blood flow, load-bearing collagen takes a long time to organise. |
| Cartilage | None (avascular) | Very poor intrinsic repair | No direct blood supply. This is why cartilage damage is managed, not healed. |
If your interest is gut-related, the research horizon is short and that is where the original Zagreb work concentrated. If your interest is a chronic tendon problem, you are looking at a months-long window no matter what. Judging a tendon outcome at four weeks is simply reading the result too early.
What the animal studies measured, and when
BPC-157 has been studied for over thirty years, overwhelmingly in animals, and mostly by one research group led by Predrag Sikirić in Zagreb. Understanding the timepoints those studies used tells you what kind of effect was being claimed.
| Model | Typical assessment window | What was measured |
|---|---|---|
| Gastric and intestinal lesions | Hours to days | Lesion area, mucosal integrity |
| Tendon and ligament transection | 1–4 weeks | Load to failure, collagen organisation, functional scores |
| Muscle crush and transection | 1–2 weeks | Muscle function, histology |
| Blood-vessel and perfusion models | Minutes to hours | Vessel recruitment, pressure changes |
Several points matter when carrying this across to a person:
- Rodents heal faster than humans. A four-week rat tendon study does not translate to a four-week human expectation.
- These were acute, surgically created injuries in healthy young animals — not years-old chronic tendinopathy in a forty-year-old.
- A 2025 systematic review in HSS Journal screened 544 articles and included 36 on musculoskeletal research. It found no adverse effects reported across organ systems, and it also noted that every included study was low-tier evidence (level IV or V).
The human evidence, in full
This section is short, because the evidence is short. Here is essentially everything published or registered.
| Study | People | Timeline reported | What it can tell you |
|---|---|---|---|
| Knee pain case series, 2021 (Altern Ther Health Med) | 16 | Retrospective follow-up | 14 of 16 reported relief. No control group, no blinding, no validated outcome measures. The authors call it preliminary. |
| Intravenous safety pilot, 2025 (Lee & Burgess) | 2 | Short | A feasibility check for safety, not an efficacy or timing study. |
| Ulcerative colitis program (PL-14736) | Phase 2 reportedly reached | Not published standalone | Full trial data was never published in a standalone peer-reviewed paper. |
| NCT02637284 | — | — | A 2015 phase 1 trial, registered and apparently cancelled without results. |
| NCT07803250 (rotator cuff, UAMS) | Planned | Not expected to start until 2027 | Registered September 2026. Randomized and placebo-controlled — the first study designed to answer this properly. |
Add it up and you get fewer than twenty people with any documented outcome, none of them in a controlled trial. When the US FDA’s own staff reviewed BPC-157 in July 2026, they described “a general lack of quality data” on safety and effectiveness. Any website giving you a confident week-by-week human timeline is not reporting evidence. It is reporting anecdote with a schedule attached.
The confounder nobody accounts for
This is the section that separates an honest guide from a sales page.
Most injuries improve on their own. That is what the data above on hamstring strains and ankle sprains is telling you: the average case is already resolving in about three weeks without any intervention at all. Pain also fluctuates. People tend to start something new when symptoms are at their worst, which is precisely the moment when the next move is statistically likely to be improvement regardless — a pattern called regression to the mean.
Stack three things on top of each other and you get the classic trap:
Any one of those produces a convincing “it worked at week four” story. All three together produce a very convincing one. This is exactly why randomized placebo-controlled trials exist, and exactly why the registered rotator-cuff trial matters more than a thousand forum posts.
What this does not mean: it does not mean nothing happened, or that everyone reporting improvement is mistaken. It means that in an uncontrolled individual case, improvement is not evidence of causation. Both things can be true: the research is genuinely interesting, and your personal n=1 cannot settle it.
Why weeks one and two mislead you
Two opposite errors happen early, and both come from the same misunderstanding.
The false positive. Something feels better within days. Because the proliferative phase has barely begun, a genuine structural change in tendon in that window is not plausible. What is plausible: the inflammatory phase settling on schedule, reduced activity, or expectation effects. Early relief is real as an experience; it just is not evidence of tissue repair.
The false negative. Nothing has changed at day ten, so the conclusion is that the vial is fake. But at day ten, for tendon, nothing should have changed structurally. Remodelling has not started. Quitting here is quitting before the only phase that would show the difference.
Four reasons someone sees nothing at week six
Week six is where most people make a judgement. If the answer is “no change,” there are four genuinely different explanations, and they call for different responses.
| Reason | How to recognise it | What it means |
|---|---|---|
| 1. Wrong tissue expectation | The target is tendon, ligament or cartilage | Week six is the start of remodelling. The evaluation is early, not negative. |
| 2. The problem is not a repair problem | Pain without a structural injury; nerve-related pain; referred pain; inflammatory arthritis | A tissue-repair mechanism has nothing to act on. This is a case for a proper diagnosis, not a longer run. |
| 3. Product quality | No batch COA, no mass spectrometry, unusually cheap | See the next section. This is the most actionable of the four. |
| 4. It does not work for this | Everything above has been excluded | Entirely possible. There is no controlled human trial showing it does. Honest guides have to leave this option on the table. |
The variable most people never check
Before concluding anything about a compound’s timeline, it is worth asking whether the compound was in the vial at the stated amount. This is not a hypothetical concern.
A 2026 analysis by Mendias and Awan evaluated research-grade peptides marketed directly to consumers and reported extensive variability in purity and in measured abundance — meaning both “is it the right molecule” and “is there as much as the label says” varied between products. Health Canada’s April 2026 advisory lists the same practical hazards for unauthorized peptides: wrong dose (too much, too little, or none at all), unlisted ingredients, and contamination with solvents, heavy metals, particles or microbes.
Check the certificate of analysis for your actual lot number. It should show HPLC purity and mass-spectrometry identity, with a molecular weight matching BPC-157 (about 1,419 Da). Purity and quantity are different numbers: a vial can be 99% pure and still contain 6 mg where the label says 10. Our COA guide walks through it line by line, and how to spot fake peptides covers the eight checks that catch most problems.
Storage has a timeline of its own
A second, quieter variable: a product that was correct when it shipped can degrade before it is used. Chemical degradation is invisible — a clear solution tells you nothing about how much intact peptide remains.
| Form | Where | Common working guidance |
|---|---|---|
| Lyophilized powder, sealed | Freezer (−20 °C) | Long term, often 1–2 years or more |
| Lyophilized powder, sealed | Fridge (2–8 °C) | Several months |
| Reconstituted, bacteriostatic water | Fridge (2–8 °C) | About 28 days |
| Reconstituted, any diluent | Room temperature | Avoid |
The 28-day figure is borrowed from pharmacy sterility rules for opened multi-dose vials containing a preservative, not from a BPC-157 stability study — we explain where it comes from in how long reconstituted BPC-157 lasts. The structural good news is that BPC-157 lacks the amino acids that drive the fastest degradation routes: no methionine, cysteine or tryptophan to oxidise, and no asparagine or glutamine to deamidate.
What would actually settle this
One study. A randomized, placebo-controlled trial with a defined injury, a validated outcome measure, and enough people to detect a real difference.
That study is now registered. NCT07803250, run at the University of Arkansas for Medical Sciences, is a randomized placebo-controlled pilot in rotator-cuff surgery recovery, registered in September 2026 and not expected to start until 2027. Results will take years after that. Until then, anyone claiming a definitive human timeline is filling a gap in the literature with confidence rather than data.
Where this stands in Canada
Separate from whether it works: BPC-157 is not an authorized drug in Canada. Health Canada regulates injectable peptides as prescription drugs and names BPC-157 directly in its April 9, 2026 public advisory on unauthorized injectable peptides. The advisory also addresses labelling head-on, stating that a “research use only” label “does not make these products legal or exempt from regulatory requirements.”
In sport, BPC-157 is prohibited at all times by WADA under category S0 (non-approved substances), and strict liability applies.
See TrueLabs BPC-157 and its batch COA →
What to track, and how often
If you are running any kind of structured observation, the single most useful habit is writing things down before you start. Memory reshapes itself around what you hope happened.
| What | How often | Why it beats “how does it feel” |
|---|---|---|
| A specific provoking movement, rated 0–10 | Weekly, same day and time | “Pain pressing overhead” is comparable week to week. “My shoulder” is not. |
| Range of motion, measured the same way | Every 2 weeks | Objective, and often improves before pain does. |
| Load tolerance at a fixed weight and rep count | Weekly | The closest practical proxy for tissue capacity. |
| Sleep, protein intake, training volume | Ongoing | These are the confounders. Logging them is the only way to separate them later. |
| Lot number and start date | Once | Ties any observation to a specific vial and COA. |
Mistakes that stretch the timeline
- Judging tendon at week three. Remodelling has not started. You are reading a chapter early.
- Changing three variables at once. New compound, new training block, new sleep schedule. Afterwards, nothing is attributable.
- Complete rest. Phase three reorganises collagen along lines of load. Appropriately graded loading is how tendon regains capacity, and a physiotherapist is the right person to set that.
- No baseline. Without a written starting point, improvement is unmeasurable and memory fills the gap.
- Letting a reconstituted vial sit warm. Degradation is invisible. See how to store peptides.
- Ignoring the actual diagnosis. If the pain is not a repair problem, no repair compound has anything to act on.
BPC-157 and TB-500 on pace
These two get paired constantly, and their pharmacology runs on different clocks.
| BPC-157 | TB-500 / thymosin beta-4 | |
|---|---|---|
| Half-life | Under 30 minutes (rats, dogs) | Longer for the full protein; the short fragment is not characterised in humans |
| Human trial data | No published RCT; fewer than 20 documented cases | Phase 1 to phase 3 for full-length Tβ4, including IV dosing in healthy volunteers |
| Main open question | Does it work in humans at all? | Long-term cancer risk, given its role in cell migration and blood-vessel growth |
| What is often sold | The studied 15-amino-acid sequence | Often a 7-amino-acid fragment, not the molecule that was trialled |
Full breakdowns: BPC-157 vs TB-500 and TB-500 side effects.
Glossary
| Half-life | The time for blood concentration to fall by half. Short half-life means fast clearance, not weak effect. |
| Fibroblast | The cell that produces collagen and the rest of the connective-tissue matrix. |
| Proliferative phase | The weeks after injury when new, disorganised collagen is laid down. |
| Remodelling phase | From about week six: collagen cross-links and reorganises along lines of load. Where strength returns. |
| Regression to the mean | The statistical tendency for an extreme measurement to be followed by a more average one. |
| Level IV / V evidence | Case series and expert opinion — the lowest tiers of the evidence hierarchy. |
| HPLC / mass spectrometry | Purity and identity testing, respectively. A COA needs both. |
Frequently asked questions
Cliquez sur une question pour afficher la réponse.
How long does BPC-157 take to work?
There is no established human answer, because no controlled human trial has measured it. What is known is the tissue timeline it would have to work within: inflammation settles over about 24 hours to a few days, new collagen is laid down over the following weeks, and remodelling does not begin until roughly week six and continues for months. Gut tissue repairs in days; tendon takes months.
Why does BPC-157 take weeks if it clears the body in 30 minutes?
Because the peptide clears quickly but the tissue it acts on does not. Collagen has to be produced, cross-linked and reorganised under load, and that process takes weeks to months regardless of what triggers it.
Is it normal to feel nothing after two weeks?
For tendon, ligament or cartilage, yes. At two weeks the remodelling phase has not started, so no structural change would be expected yet.
How do I know if my BPC-157 is real?
Check the batch-specific certificate of analysis: it should name the testing lab and show both HPLC purity and mass-spectrometry identity, with a molecular weight of about 1,419 Da and the lot number matching your vial. A 2026 analysis found wide variation in purity and actual content across consumer research peptides.
Does BPC-157 work faster for gut issues than for tendons?
The gut lining turns over in days and is richly supplied with blood, while tendon is poorly vascularised and remodels over months. Most of the original BPC-157 research was in gastrointestinal models.
If my injury improved, was it the BPC-157?
In an uncontrolled individual case you cannot know. Most soft-tissue injuries improve on their own — average return to play is around three weeks for hamstring strains — and people typically start something new when symptoms are worst, which is when improvement is most likely anyway.
Should I keep going if nothing has changed at six weeks?
That depends on which of four things is happening: the tissue timeline is longer than six weeks, the problem is not a repair problem, the product quality is in question, or it does not work for this. Those call for different responses, and a doctor or physiotherapist can help distinguish the first two.
Does BPC-157 build up in your system over time?
No. Its half-life is under 30 minutes in animal studies and it is cleared rapidly without accumulating. That is the opposite of long-acting peptides such as CJC-1295 with DAC, which has a half-life of roughly 6 to 8 days.
How long does reconstituted BPC-157 stay good?
A common working rule is about 28 days refrigerated at 2–8 °C when reconstituted with bacteriostatic water. That figure comes from pharmacy sterility rules for multi-dose vials, not from a published BPC-157 stability study.
Is BPC-157 legal in Canada?
It is not authorized by Health Canada, which names it in its April 2026 advisory on unauthorized injectable peptides and states that “research use only” labelling does not make these products legal or exempt from regulatory requirements.
Is BPC-157 banned in sport?
Yes. WADA prohibits it at all times under category S0, non-approved substances, and strict liability applies.
When will there be a real answer on whether it works?
A randomized, placebo-controlled pilot in rotator-cuff surgery recovery (NCT07803250) was registered in September 2026 and is not expected to start until 2027, so results are years away.
Related reading
- BPC-157 and TB-500 together: the Wolverine stack guide
- BPC-157 side effects: what the research actually shows
- BPC-157 vs TB-500: roads vs trucks
- How long does reconstituted BPC-157 last?
- How to spot fake or underdosed peptides
- Buy BPC-157 in Canada: price, purity and research
References
- He L, Feng D, Guo H, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157 in rats and dogs. Front Pharmacol. 2022;13:1026182. PubMed
- Xu C, Sun L, Ren F, et al. Preclinical safety evaluation of body protective compound-157. Regul Toxicol Pharmacol. 2020;114:104665. DOI
- Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS J. 2025. PubMed
- Intra-articular injection of BPC 157 for multiple types of knee pain. Altern Ther Health Med. 2021;27(4):8–13. PubMed
- Mendias CL, Awan TM. Evaluation of research grade peptides marketed directly to consumers reveals extensive variability in purity and measured abundance. Preprints.org. April 2026 (not peer-reviewed). Preprint
- ShoulderDoc. Tendon healing mechanobiology (phases and time windows). ShoulderDoc
- Better Health Channel (Victoria, AU). Sprains and strains: healing and return-to-play timeframes. Better Health Channel
- ClinicalTrials.gov. NCT07803250 and NCT02637284. ClinicalTrials.gov
- Health Canada. Think twice before injecting peptides bought online. Public advisory, April 9, 2026. Health Canada
All TrueLabs products are sold for in vitro and laboratory research use only. They are not intended for human or veterinary use, and nothing in this article is medical advice or a dosing protocol. If you are dealing with an injury or chronic pain, a doctor or physiotherapist can offer treatments with real evidence behind them.